Your browser doesn't support javascript.
loading
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
Garcia-Foncillas, Jesus; Bokemeyer, Carsten; Italiano, Antoine; Keating, Karen; Paracha, Noman; Fellous, Marc; Marian, Marisca; Fillbrunn, Mirko; Gao, Wei; Ayyagari, Rajeev; Lassen, Ulrik.
Affiliation
  • Garcia-Foncillas J; Department of Oncology, Cancer Institute, Fundacion Jimenez Diaz University Hospital, Autonomous University, 28040 Madrid, Spain.
  • Bokemeyer C; Department of Oncology, Hematology and BMT with Section Penumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Italiano A; Early Phase Trials Unit, Institut Bergonie, 33000 Bordeaux, France.
  • Keating K; Faculty of Medicine, University of Bordeaux, 33000 Bordeaux, France.
  • Paracha N; Bayer HealthCare Pharmaceuticals, Inc., Whippany, Hanover Township, NJ 07981, USA.
  • Fellous M; Market Access Oncology, Bayer AG, 4052 Basel, Switzerland.
  • Marian M; Market Access Oncology, Bayer AG, 4052 Basel, Switzerland.
  • Fillbrunn M; Market Access Oncology, Bayer AG, 4052 Basel, Switzerland.
  • Gao W; Analysis Group, Inc., Boston, MA 02199, USA.
  • Ayyagari R; Analysis Group, Inc., Boston, MA 02199, USA.
  • Lassen U; Analysis Group, Inc., Boston, MA 02199, USA.
Cancers (Basel) ; 14(7)2022 Mar 31.
Article in En | MEDLINE | ID: mdl-35406565
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: